ArticleInternational journal of cancer2026
Survival outcomes and prognostic factors of gastric carcinoma with neuroendocrine differentiation.
Article in International journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Gastrointestinal conventional carcinoma with neuroendocrine differentiation: From pathological phenomenon to clinical importance (Review).Oncology letters · 2026Review
- Survival outcomes and prognostic factors of gastric carcinoma with neuroendocrine differentiation.International journal of cancer · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
Abstract
Gastric carcinoma (GC) with neuroendocrine differentiation (GCNED) is a rare and particular pathological subtype. The survival outcomes and prognosis of patients with GCNED are currently unclear. We conducted a retrospective cohort study including 309 patients with GC diagnosed between 2012 and 2024 to clarify outcomes after radical resections. Neuroendocrine differentiation was identified using immunohistochemical staining for synaptophysin, chromogranin A, and neural cell adhesion molecule expression. The results showed a GCNED-positivity rate of 22.3% (69/309). The only significant difference in clinicopathological characteristics was the higher perineural invasion (PNI) rate in patients with GCNED-positivity (29% vs. 15.8%, p = .014). Factors such as age, sex, TNM stage, and lymphovascular invasion showed no differences. Regardless of the GCNED-positivity cutoff value (1%, 10%, or 20%), no statistically significant differences in overall survival (OS) or recurrence-free survival (RFS) rates were observed between the two groups. However, in the differentiated histology group, patients with GCNED-positivity showed worse survival rates (p = .015). Logistic regression identified PNI as an independent risk factor for GCNED positivity (odds ratio, 2.08; 95% confidence interval, 1.11-3.91; p = .022). The study showed that while GCNED has a non-negligible prevalence, it has no significant effect on OS or RFS outcomes for patients after radical resections compared to GC without neuroendocrine features. The trend toward a worse prognosis in specific subgroups, such as patients with differentiated GCNED, suggests biological heterogeneity and warrants a longer follow-up to inform stratified therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.